126 related articles for article (PubMed ID: 33826578)
21. Juvenile angiofibroma: the lessons of 20 years of modern imaging.
Lloyd G; Howard D; Phelps P; Cheesman A
J Laryngol Otol; 1999 Feb; 113(2):127-34. PubMed ID: 10396561
[TBL] [Abstract][Full Text] [Related]
22. PET/CT With
Giovacchini G; Giovannini E; Riondato M; Ciarmiello A
Curr Radiopharm; 2018; 11(1):4-13. PubMed ID: 29090673
[TBL] [Abstract][Full Text] [Related]
23. The Impact of 68Ga-PSMA PET/CT and PET/MRI on the Management of Prostate Cancer.
Hoffmann MA; Wieler HJ; Baues C; Kuntz NJ; Richardsen I; Schreckenberger M
Urology; 2019 Aug; 130():1-12. PubMed ID: 30986486
[TBL] [Abstract][Full Text] [Related]
24.
Donato P; Morton A; Yaxley J; Ranasinghe S; Teloken PE; Kyle S; Coughlin G; Esler R; Dunglison N; Gardiner RA; Roberts MJ
Eur J Nucl Med Mol Imaging; 2020 Jul; 47(8):1843-1851. PubMed ID: 31912257
[TBL] [Abstract][Full Text] [Related]
25. Incidental Meningioma Mimicking Metastasis of Prostate Adenocarcinoma in 68Ga-Labeled PSMA Ligand PET/CT.
Bilgin R; Ergül N; Çermik TF
Clin Nucl Med; 2016 Dec; 41(12):956-958. PubMed ID: 27824323
[TBL] [Abstract][Full Text] [Related]
26. Comparison of 68Ga-PSMA-I/T PET-CT and Multiparametric MRI for Locoregional Staging of Prostate Cancer Patients: A Pilot Study.
Çelen S; Gültekin A; Özlülerden Y; Mete A; Sağtaş E; Ufuk F; Yüksel D; Yağcı B; Zümrütbaş AE
Urol Int; 2020; 104(9-10):684-691. PubMed ID: 32750695
[TBL] [Abstract][Full Text] [Related]
27. Comparison of preoperative locoregional Ga-68 PSMA-11 PET-CT and mp-MRI results with postoperative histopathology of prostate cancer.
Yilmaz B; Turkay R; Colakoglu Y; Baytekin HF; Ergul N; Sahin S; Tugcu V; Inci E; Tasci AI; Cermik TF
Prostate; 2019 Jun; 79(9):1007-1017. PubMed ID: 31012125
[TBL] [Abstract][Full Text] [Related]
28. Comparison of 68Ga-PSMA PET/CT and multiparametric MRI for staging of high-risk prostate cancer68Ga-PSMA PET and MRI in prostate cancer.
Tulsyan S; Das CJ; Tripathi M; Seth A; Kumar R; Bal C
Nucl Med Commun; 2017 Dec; 38(12):1094-1102. PubMed ID: 28957842
[TBL] [Abstract][Full Text] [Related]
29. Recurrent and residual juvenile angiofibromas.
Tyagi I; Syal R; Goyal A
J Laryngol Otol; 2007 May; 121(5):460-7. PubMed ID: 17210091
[TBL] [Abstract][Full Text] [Related]
30. Accuracy of 68Ga-PSMA PET-CT and PET-MRI in lymph node staging for localized prostate cancer.
Barbosa ÁRG; Amaral BS; Lourenço DB; Bianco B; Gushiken FA; Apezzato M; Silva JF; Cunha MLD; Filippi RZ; Baroni RH; Lemos GC; Carneiro A
Einstein (Sao Paulo); 2022; 20():eAO6599. PubMed ID: 35584444
[TBL] [Abstract][Full Text] [Related]
31. Prostate-specific membrane antigen positron emission tomography in the management of recurrent prostate cancer.
Afaq A; Bomanji J
Br Med Bull; 2018 Dec; 128(1):37-48. PubMed ID: 30272121
[TBL] [Abstract][Full Text] [Related]
32.
Pfister D; Haidl F; Nestler T; Verburg F; Schmidt M; Wittersheim M; Steib F; Heidenreich A
BJU Int; 2020 Dec; 126(6):679-683. PubMed ID: 32531840
[TBL] [Abstract][Full Text] [Related]
33. A Prospective Comparison of
Anttinen M; Ettala O; Malaspina S; Jambor I; Sandell M; Kajander S; Rinta-Kiikka I; Schildt J; Saukko E; Rautio P; Timonen KL; Matikainen T; Noponen T; Saunavaara J; Löyttyniemi E; Taimen P; Kemppainen J; Dean PB; Blanco Sequeiros R; Aronen HJ; Seppänen M; Boström PJ
Eur Urol Oncol; 2021 Aug; 4(4):635-644. PubMed ID: 32675047
[TBL] [Abstract][Full Text] [Related]
34. In primary lymph nodal staging of patients with high-risk and intermediate-risk prostate cancer, how critical is the role of Gallium-68 prostate-specific membrane antigen positron emission tomography-computed tomography?
Kulkarni SC; Sundaram PS; Padma S
Nucl Med Commun; 2020 Feb; 41(2):139-146. PubMed ID: 31714366
[TBL] [Abstract][Full Text] [Related]
35. Fusion 68Ga-DOTANOC PET/MRI in Primary Juvenile Nasal Angiofibroma.
Sakthivel P; Thakar A; Arunraj ST; Bhalla AS; Prashanth A; Kumar R
Clin Nucl Med; 2021 Jul; 46(7):e389-e390. PubMed ID: 33630795
[TBL] [Abstract][Full Text] [Related]
36. Early PET imaging with [68]Ga-PSMA-11 increases the detection rate of local recurrence in prostate cancer patients with biochemical recurrence.
Uprimny C; Kroiss AS; Fritz J; Decristoforo C; Kendler D; von Guggenberg E; Nilica B; Maffey-Steffan J; di Santo G; Bektic J; Horninger W; Virgolini IJ
Eur J Nucl Med Mol Imaging; 2017 Sep; 44(10):1647-1655. PubMed ID: 28589253
[TBL] [Abstract][Full Text] [Related]
37. Multiphasic
Beheshti M; Manafi-Farid R; Geinitz H; Vali R; Loidl W; Mottaghy FM; Langsteger W
J Nucl Med; 2020 Oct; 61(10):1484-1490. PubMed ID: 32060214
[TBL] [Abstract][Full Text] [Related]
38.
Hruby G; Eade T; Emmett L; Ho B; Hsiao E; Schembri G; Guo L; Kwong C; Hunter J; Byrne K; Kneebone A
Asia Pac J Clin Oncol; 2018 Aug; 14(4):343-346. PubMed ID: 29663686
[TBL] [Abstract][Full Text] [Related]
39. Modelling Study with an Interactive Model Assessing the Cost-effectiveness of
Scholte M; Barentsz JO; Sedelaar JPM; Gotthardt M; Grutters JPC; Rovers MM
Eur Urol Focus; 2020 Sep; 6(5):967-974. PubMed ID: 30826284
[TBL] [Abstract][Full Text] [Related]
40. Spurious Uptake on 68Ga-Prostate-Specific Membrane Antigen PET/CT Due to Ankylosing Spondylitis; A Rare Pitfall in Imaging of Biochemical Recurrence of Prostate Cancer.
Heaney RM; Johnston C; Nasoodi A
Clin Nucl Med; 2021 Jul; 46(7):e373-e375. PubMed ID: 33782312
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
